This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balachandran, S.
Right arrow Articles by Barber, G. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balachandran, S.
Right arrow Articles by Barber, G. N.

 Previous Article  |  Next Article 

Journal of Virology, April 2001, p. 3474-3479, Vol. 75, No. 7
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.7.3474-3479.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Oncolytic Activity of Vesicular Stomatitis Virus Is Effective against Tumors Exhibiting Aberrant p53, Ras, or Myc Function and Involves the Induction of Apoptosis

Siddharth Balachandran, Mercedes Porosnicu, and Glen N. Barber*

Department of Microbiology and Immunology and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida 33136

Received 3 November 2000/Accepted 9 January 2001

We have recently shown that vesicular stomatitis virus (VSV) exhibits potent oncolytic activity both in vitro and in vivo (S. Balachandran and G. N. Barber, IUBMB Life 50:135-138, 2000). In this study, we further demonstrated, in vivo, the efficacy of VSV antitumor action by showing that tumors that are defective in p53 function or transformed with myc or activated ras are also susceptible to viral cytolysis. The mechanism of viral oncolytic activity involved the induction of multiple caspase-dependent apoptotic pathways was effective in the absence of any significant cytotoxic T-lymphocyte response, and occurred despite normal PKR activity and eIF2alpha phosphorylation. In addition, VSV caused significant inhibition of tumor growth when administered intravenously in immunocompetent hosts. Our data indicate that VSV shows significant promise as an effective oncolytic agent against a wide variety of malignant diseases that harbor a diversity of genetic defects.

* Corresponding author. Mailing address: Rm. 514, Papanicolaou Building, 1550 NW 10th Ave. [M710], University of Miami School of Medicine, Miami, FL 33136. Phone: (305) 243-5914. Fax: (305) 243-5885. E-mail: gbarber{at}med.miami.edu.

Journal of Virology, April 2001, p. 3474-3479, Vol. 75, No. 7
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.7.3474-3479.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Ozduman, K., Wollmann, G., Ahmadi, S. A., van den Pol, A. N. (2009). Peripheral Immunization Blocks Lethal Actions of Vesicular Stomatitis Virus within the Brain. J. Virol. 83: 11540-11549 [Abstract] [Full Text]  
  • Willmon, C. L., Saloura, V., Fridlender, Z. G., Wongthida, P., Diaz, R. M., Thompson, J., Kottke, T., Federspiel, M., Barber, G., Albelda, S. M., Vile, R. G. (2009). Expression of IFN-{beta} Enhances Both Efficacy and Safety of Oncolytic Vesicular Stomatitis Virus for Therapy of Mesothelioma. Cancer Res. 69: 7713-7720 [Abstract] [Full Text]  
  • Pearce, A. F., Lyles, D. S. (2009). Vesicular Stomatitis Virus Induces Apoptosis Primarily through Bak Rather than Bax by Inactivating Mcl-1 and Bcl-XL. J. Virol. 83: 9102-9112 [Abstract] [Full Text]  
  • Christian, S. L., Collier, T. W., Zu, D., Licursi, M., Hough, C. M., Hirasawa, K. (2009). Activated Ras/MEK Inhibits the Antiviral Response of Alpha Interferon by Reducing STAT2 Levels. J. Virol. 83: 6717-6726 [Abstract] [Full Text]  
  • Carey, B. L., Ahmed, M., Puckett, S., Lyles, D. S. (2008). Early Steps of the Virus Replication Cycle Are Inhibited in Prostate Cancer Cells Resistant to Oncolytic Vesicular Stomatitis Virus. J. Virol. 82: 12104-12115 [Abstract] [Full Text]  
  • Zhao, J.-m., Wen, Y.-j., Li, Q., Wang, Y.-s., Wu, H.-b., Xu, J.-r., Chen, X.-c., Wu, Y., Fan, L.-y., Yang, H.-s., Liu, T., Ding, Z.-y., Du, X.-b., Diao, P., Li, J., Wu, H.-b., Kan, B., Lei, S., Deng, H.-x., Mao, Y.-q., Zhao, X., Wei, Y.-q. (2008). A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. FASEB J. 22: 4272-4280 [Abstract] [Full Text]  
  • Alajez, N. M., Mocanu, J. D., Shi, W., Chia, M. C., Breitbach, C. J., Hui, A. B.Y., Knowles, S., Bell, J. C., Busson, P., Takada, K., Lo, K.-W., O'Sullivan, B., Gullane, P., Liu, F.-F. (2008). Efficacy of Systemically Administered Mutant Vesicular Stomatitis Virus (VSV{Delta}51) Combined with Radiation for Nasopharyngeal Carcinoma. Clin. Cancer Res. 14: 4891-4897 [Abstract] [Full Text]  
  • Ozduman, K., Wollmann, G., Piepmeier, J. M., van den Pol, A. N. (2008). Systemic Vesicular Stomatitis Virus Selectively Destroys Multifocal Glioma and Metastatic Carcinoma in Brain. J. Neurosci. 28: 1882-1893 [Abstract] [Full Text]  
  • Goel, A., Carlson, S. K., Classic, K. L., Greiner, S., Naik, S., Power, A. T., Bell, J. C., Russell, S. J. (2007). Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV({Delta}51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 110: 2342-2350 [Abstract] [Full Text]  
  • Irie, T., Carnero, E., Okumura, A., Garcia-Sastre, A., Harty, R. N. (2007). Modifications of the PSAP region of the matrix protein lead to attenuation of vesicular stomatitis virus in vitro and in vivo. J. Gen. Virol. 88: 2559-2567 [Abstract] [Full Text]  
  • Diaz, R. M., Galivo, F., Kottke, T., Wongthida, P., Qiao, J., Thompson, J., Valdes, M., Barber, G., Vile, R. G. (2007). Oncolytic Immunovirotherapy for Melanoma Using Vesicular Stomatitis Virus. Cancer Res. 67: 2840-2848 [Abstract] [Full Text]  
  • Gaddy, D. F., Lyles, D. S. (2007). Oncolytic Vesicular Stomatitis Virus Induces Apoptosis via Signaling through PKR, Fas, and Daxx. J. Virol. 81: 2792-2804 [Abstract] [Full Text]  
  • Wollmann, G., Robek, M. D., van den Pol, A. N. (2007). Variable Deficiencies in the Interferon Response Enhance Susceptibility to Vesicular Stomatitis Virus Oncolytic Actions in Glioblastoma Cells but Not in Normal Human Glial Cells. J. Virol. 81: 1479-1491 [Abstract] [Full Text]  
  • Lun, X., Senger, D. L., Alain, T., Oprea, A., Parato, K., Stojdl, D., Lichty, B., Power, A., Johnston, R. N., Hamilton, M., Parney, I., Bell, J. C., Forsyth, P. A. (2006). Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV{Delta}M51) on Multifocal and Invasive Gliomas.. JNCI J Natl Cancer Inst 98: 1546-1557 [Abstract] [Full Text]  
  • Elankumaran, S., Rockemann, D., Samal, S. K. (2006). Newcastle Disease Virus Exerts Oncolysis by both Intrinsic and Extrinsic Caspase-Dependent Pathways of Cell Death.. J. Virol. 80: 7522-7534 [Abstract] [Full Text]  
  • Majid, A. M., Ezelle, H., Shah, S., Barber, G. N. (2006). Evaluating Replication-Defective Vesicular Stomatitis Virus as a Vaccine Vehicle. J. Virol. 80: 6993-7008 [Abstract] [Full Text]  
  • Battcock, S. M., Collier, T. W., Zu, D., Hirasawa, K. (2006). Negative Regulation of the Alpha Interferon-Induced Antiviral Response by the Ras/Raf/MEK Pathway. J. Virol. 80: 4422-4430 [Abstract] [Full Text]  
  • Ahmed, M., Brzoza, K. L., Hiltbold, E. M. (2006). Matrix Protein Mutant of Vesicular Stomatitis Virus Stimulates Maturation of Myeloid Dendritic Cells. J. Virol. 80: 2194-2205 [Abstract] [Full Text]  
  • Shinozaki, K., Ebert, O., Suriawinata, A., Thung, S. N., Woo, S. L. C. (2005). Prophylactic Alpha Interferon Treatment Increases the Therapeutic Index of Oncolytic Vesicular Stomatitis Virus Virotherapy for Advanced Hepatocellular Carcinoma in Immune-Competent Rats. J. Virol. 79: 13705-13713 [Abstract] [Full Text]  
  • Wollmann, G., Tattersall, P., van den Pol, A. N. (2005). Targeting Human Glioblastoma Cells: Comparison of Nine Viruses with Oncolytic Potential. J. Virol. 79: 6005-6022 [Abstract] [Full Text]  
  • Connor, J. H., Naczki, C., Koumenis, C., Lyles, D. S. (2004). Replication and Cytopathic Effect of Oncolytic Vesicular Stomatitis Virus in Hypoxic Tumor Cells In Vitro and In Vivo. J. Virol. 78: 8960-8970 [Abstract] [Full Text]  
  • Ebert, O., Shinozaki, K., Kournioti, C., Park, M.-S., Garcia-Sastre, A., Woo, S. L. C. (2004). Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer. Cancer Res. 64: 3265-3270 [Abstract] [Full Text]  
  • Porosnicu, M., Mian, A., Barber, G. N. (2003). The Oncolytic Effect of Recombinant Vesicular Stomatitis Virus Is Enhanced by Expression of the Fusion Cytosine Deaminase/Uracil Phosphoribosyltransferase Suicide Gene. Cancer Res. 63: 8366-8376 [Abstract] [Full Text]  
  • Sur, J.-H., Allende, R., Doster, A. R. (2003). Vesicular Stomatitis Virus Infection and Neuropathogenesis in the Murine Model are Associated with Apoptosis. Vet Pathol 40: 512-520 [Abstract] [Full Text]  
  • Obuchi, M., Fernandez, M., Barber, G. N. (2003). Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic Activity. J. Virol. 77: 8843-8856 [Abstract] [Full Text]  
  • Ebert, O., Shinozaki, K., Huang, T.-G., Savontaus, M. J., Garcia-Sastre, A., Woo, S. L. C. (2003). Oncolytic Vesicular Stomatitis Virus for Treatment of Orthotopic Hepatocellular Carcinoma in Immune-competent Rats. Cancer Res. 63: 3605-3611 [Abstract] [Full Text]  
  • Kopecky, S. A., Lyles, D. S. (2003). Contrasting Effects of Matrix Protein on Apoptosis in HeLa and BHK Cells Infected with Vesicular Stomatitis Virus Are due to Inhibition of Host Gene Expression. J. Virol. 77: 4658-4669 [Abstract] [Full Text]  
  • Hirasawa, K., Nishikawa, S. G., Norman, K. L., Coffey, M. C., Thompson, B. G., Yoon, C.-S., Waisman, D. M., Lee, P. W. K. (2003). Systemic Reovirus Therapy of Metastatic Cancer in Immune-competent Mice. Cancer Res. 63: 348-353 [Abstract] [Full Text]  
  • Connor, J. H., Lyles, D. S. (2002). Vesicular Stomatitis Virus Infection Alters the eIF4F Translation Initiation Complex and Causes Dephosphorylation of the eIF4E Binding Protein 4E-BP1. J. Virol. 76: 10177-10187 [Abstract] [Full Text]  
  • Chacko, M. S., Ma, X., Adamo, M. L. (2002). Double-Stranded Ribonucleic Acid Decreases C6 Rat Glioma Cell Proliferation in Part by Activating Protein Kinase R and Decreasing Insulin-Like Growth Factor I Levels. Endocrinology 143: 2144-2154 [Abstract] [Full Text]  
  • Chacko, M. S., Adamo, M. L. (2002). Double-Stranded RNA Decreases IGF-I Gene Expression in a Protein Kinase R-Dependent, but Type I Interferon-Independent, Mechanism in C6 Rat Glioma Cells. Endocrinology 143: 525-534 [Abstract] [Full Text]  
  • Fernandez, M., Porosnicu, M., Markovic, D., Barber, G. N. (2002). Genetically Engineered Vesicular Stomatitis Virus in Gene Therapy: Application for Treatment of Malignant Disease. J. Virol. 76: 895-904 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»